Drug Trial Radar · NCT01724866
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
Last checked: Nov 20, 2026Latest source record: Apr 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
148
Actual
Start
Mar 25, 2013
Primary completion
Aug 12, 2014
Study completion Aug 12, 2014
Sponsor
- Lead sponsor
- Spectrum Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 12, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effect of test doses of SPI-2012 on the duration of severe neutropenia (DSN) during Cycle 1 in participants with breast cancer who are candidates for adjuvant or neoadjuvant chemotherapy.
Conditions
- Neutropenia
Interventions
SPI-2012Drug
SPI-2012 SC injection.
PegfilgrastimDrug
Pegfilgrastim SC injection, per manufacturer's Prescribing Information.
DocetaxelDrug
Docetaxel given based on standard dose for chemotherapy.
CyclophosphamideDrug
Cyclophosphamide given based on standard dose for chemotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of Severe Neutropenia (DSN) in Cycle 1Time frame: Cycle 1 (each cycle was 21 days)
Locations
27 sites in 6 countries. Site status is shown where the registry gives one.
Arizona Center for Cancer Care
Glendale, Arizona
Desert Springs Cancer Care
Scottsdale, Arizona
California Cancer Associates for Research and Excellence
Fresno, California
Beaver Medical Group
Highland, California
California Cancer Associates for Research and Excellence
Los Angeles, California
Innovative Clinical Research Institute
Whittier, California
Kentucky Cancer Clinic
Hazard, Kentucky
New York Oncology Hematology, PC
Albany, New York
North Shore Hematology/Oncology Associates
Setauket, New York
Good Samaritan Hospital, Corvallis
Corvallis, Oregon
Royal Hobart
Brisbane, Australia
Ashford Cancer Center Research
Kurralta Park, Australia
Breast Cancer Research Center, WA
Perth, Australia
Ballarat Oncology & Haematology
Wendouree, Australia
Frankston Hospital
Frankston, Victoria, Australia
LTD " Cancer Center of Adjara Autonomic Republic"
Batumi, Georgia
Ltd ' Medulla - Chemotherapy and Immunotherapy Clinic
Tbilisi, Georgia
State Health Center
Budapest, Hungary
National Institute of Oncology
Budapest, Hungary
Uzsoki Hospital
Budapest, Hungary
University Debrecen, Oncology Clinic
Debrecen, Hungary
Szabolcs - Szatmár - Bereg megyei Kórházak és Egyetemi Oktatókórház
Nyíregyháza, Hungary
Ziv Medical Center
Safed, Israel
Regionalny Szpital Specjalistyczny
Grudziądz, Poland
Szpital Uniwersytecki w Krakowie
Krakow, Poland
Dzienny Oddział Chemioterapii
Racibórz, Poland
MTZ Clinical Research Sp. z o.o.
Warsaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.